Table 2.
Characteristics of irAEs
| All Patients (n=201) | |
|---|---|
| Potential irAEs, n (mean by patient) | |
| Total | 391 (1.95) |
| With prior IMS consultation | 243 (1.88) |
| Without prior IMS consultation | 148 (2.06) |
| Potential irAEs by patient | |
| Median (IQR: 25–75th) | 2 (1–3) |
| Patients with potential irAEs, n (%) | |
| Yes | 165 (82) |
| With prior IMS consultation | 102 (79% of 129) |
| Without prior IMS consultation | 63 (88% of 72) |
| AE sites, n (%)* | (n=391)* |
| Endocrine | 26 (7) |
| HPA axis | 1 (<1) |
| Pancreas (diabetes) | 1 (<1) |
| Thyroid | 24 (6) |
| Dermatological | 70 (18)* |
| Skin | 61 (16) |
| Mucosa | 12 (3) |
| Rheumatological | 33 (8)* |
| Joints | 23 (6) |
| Muscles | 14 (4) |
| Liver | 19 (5) |
| Gastrointestinal | 82 (21) |
| Lungs | 75 (19) |
| Catheter | 36 (9) |
| Port-a-Cath | 27 (7) |
| PICC line | 9 (2) |
| Other sites | 163 (42)* |
| Cardiovascular | 9 (2) |
| Kidneys | 1 (<1) |
| Haematological | 26 (7) |
| Systemic (whole body) | 84 (21) |
| Hydroelectrolytic | 3 (<1) |
| Immunological | 2 (<1) |
| Nerves | 1 (<1) |
| Neuro-psychiatric | 22 (6) |
| Otorhinolaryngological | 13 (3) |
| Change in taste | 5 (1) |
| Sexual | 1 (<1) |
| Teeth | 1 (<1) |
| Urological | 10 (3) |
| Infection associated AEs, n (%) | 118 (30) |
| Estimated AE grade | |
| Grade 1 | 155 (40) |
| Grade 2 | 117 (30) |
| Grade 3 | 94 (24) |
| Grade 4 | 9 (2) |
| Grade 5 | 15 (4) |
| Not estimable | 1 (<1) |
| Estimated probability of being an irAE | |
| Unlikely | 98 (25) |
| Likely | 183 (47) |
| Very likely | 81 (21) |
| Almost confirmed | 29 (7) |
| Time until AE | |
| Median (IQR: 25–75th) | 4 (2–9) |
| Depending on estimated severity | |
| Grade 1 | 4 (2–8) |
| Grade 2 | 3 (2–9) |
| Grade 3 | 4 (2–7) |
| Grade 4 | 2 (2–8) |
| Grade 5 | 2 (1–2) |
Note: *One AE could involve several sites.
Abbreviations: AE, adverse event; HPA axis, hypothalamic–pituitary–adrenal axis; IQR, interquartile range; irAE, immune-related adverse event; PICC line, peripherally inserted central catheter line.